IP, Market Value and Start-ups

The proposal of SPRIND (German Agency for Disruptive Innovations) to license IP for virtual shares as a standard procedure for start-ups has not met with universal approval. How applicable is such a model to biotechnology start-ups, and can a one-size-fits-all approach really do away with defining market value and negotiating fair and reasonable IP terms? After a keynote, representatives of SPRIND, universities and technology transfer experts will share their experience and discuss their various approaches to start-up creation.